MTD

Mettler Toledo

$1,684.64

+0.40% Oct 22 close

Health CareS&P 500 Compare Technicals

1M 3M 6M 1Y 2Y

MTDSPY

+2.8%

+13.0%

+26.5%

+33.2%

YTD

+20.8%

+21.9%

Live chart

Loading live chart…

What they do

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters.

Healthcare · Diagnostics & Research

For information only · Important disclosures

Grades vs sector

Momentum

38th percentile in sector

C-

12-1 return: +6.7%
Percentile within its GICS sector across the S&P 1500.

Growth

24th percentile in sector

Revenue growth (YoY): +4.5%
Percentile within its GICS sector across the S&P 1500.

Value

17th percentile in sector

Forward E/P: 3.2% · EBITDA/EV: 3.7%
Percentile within its GICS sector across the S&P 1500.

Profitability

84th percentile in sector

A-

Profit margin: +21.9% · Return on equity: –
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

ranked 219 of 499 · 12-month momentum 14.5%

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

No recent headlines.

Key stats

52-week range$1,025.53 – $1,684.64

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans expensive

Model read-out from the numbers below, not advice. Score -2 (DCF counts double).

▼DCF (base case)below the price by 70%

•Piotroski F-score6/9

Discounted cash flow

Bear

$282

-83%

growth -4% · disc. 10.2% · term. 2.0%

Base

$499

-70%

growth 1% · disc. 9.2% · term. 2.5%

Bull

$792

-53%

growth 4% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

60.3%

Operating margin

–

FCF margin

20.9%

Net margin

21.9%

Return on equity

7062.4%

Return on invested capital

–

Net debt / EBITDA

–

Current ratio

1.1×

Interest cover

–

Cash conversion (OCF/NI)

1.1×

Piotroski F-score 6/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.0B	$869.2M	$848.6M
2024	$3.9B	$863.1M	$864.4M
2023	$3.8B	$788.8M	$860.6M
2022	$3.9B	$872.5M	$737.8M
2021	$3.7B	$769.0M	$801.2M
2020	$3.1B	$602.7M	$632.2M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +0.9%.

Earnings

Next report: 2026-11-05 · during market · EPS est 12.10

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-30	10.80	11.46	+6.1%
2026-05-07	8.71	8.91	+2.3%
2026-02-05	12.81	13.36	+4.3%
2025-11-06	10.66	11.15	+4.6%
2025-07-31	9.60	10.09	+5.1%
2025-05-01	7.88	8.19	+3.9%
2025-02-06	11.72	12.41	+5.8%
2024-11-07	10.01	10.21	+1.9%

Insider trades

Kaltenbach Patrick

President and CEO · 2026-08-27

Sell
$1.3M

Salice Thomas P

Director · 2026-08-05

Sell
$600.7K

Vadala Shawn

Chief Financial Officer · 2026-08-03

Sell
$3.2M

Keller Gerry

Head of Process Analytics · 2026-08-03

Sell
$342.5K

Salice Thomas P

Director · 2026-08-03

Sell
$599.5K

None

None · None

Sell
–

Stats refreshed 2026-10-21 18:18:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it works Terms Privacy Data status Send feedback

Beta 0.9 · Oct 21, 2026

MTD